Pulmonary Arterial Hypertension Market Size, Share & Trends Report

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase 5), And Segment Forecasts, 2020 - 2027

  • Published Date: Feb, 2020
  • Base Year for Estimate: 2019
  • Report ID: GVR-2-68038-855-8
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2018
  • Number of Pages: 112

Report Overview

The global pulmonary arterial hypertension market size was valued at USD 6.3 billion in 2019. It is expected to register a CAGR of 5.6% over the forecast period. Rising prevalence of Pulmonary Arterial Hypertension (PAH), robust drug pipeline, changing lifestyle, and increasing geriatric population is expected to drive the market during the forecast period.

Supportive government initiatives for the development of orphan drugs (drugs for rare diseases) are projected to support the market for pulmonary arterial hypertension. For instance, the Rare Disease Act 2002 and the Orphan Drug Act (ODA) 1983 in the U.S. offer incentives such as tax credits for the development of orphan drugs. The Orphan Drug Act enables tax credits up to 50.0% of total R&D cost, funding for R&D, protocol assistance, waiver in FDA fees, and clinical tax incentives. These incentives encouraged pharmaceutical companies to invest in the development of orphan drugs for treating PAH.

U.S. pulmonary arterial hypertension market

The Patient-Focused Drug Development initiative highlights the power of and advocacy for patient care in the U.S. This initiative helped understand disease severity, impact of the disease on patients’ lives, and available treatment options for diseases such as pulmonary arterial hypertension. This initiative also helped create awareness about rare diseases in the U.S., which helped people undergo diagnosis and avail treatment of rare diseases, including PAH.

In September 2019, Acceleron Pharma, Inc. received FDA orphan drug designation for Sotatercept for the treatment of pulmonary arterial hypertension. Sotatercept was evaluated in two Phase 2 trials: the PULSAR trial and the SPECTRA exploratory trial. The company met its primary and key secondary endpoints in patients with pulmonary arterial hypertension in January 2020. Innovations such as these are anticipated to drive the overall market for PAH treatment over the forecast period.

Changes in lifestyle such as excessive alcohol consumption, lack of physical activity, smoking, and consumption of fast food increase the risk of hypertension and high blood pressure. Increased blood pressure subsequently gives rise to various diseases such as stroke, heart attacks, and pulmonary arterial hypertension. Pulmonary arterial hypertension is perceived as a variable health risk and is often related with morbidity and mortality due to its alliance with cardiovascular diseases. Furthermore, PAH is hard to detect as the symptoms of pulmonary arterial hypertension are often mild or nonspecific.

Drug Class Insights

On the basis of drug class, the pulmonary arterial hypertension (PAH) market has been segmented into Soluble Guanylate Cyclase (SGC) stimulators, prostacyclin and prostacyclin analogs, phosphodiesterase 5 (PDE-5), and Endothelin Receptor Antagonists (ERA). ERA and prostacyclin and prostacyclin analogs for treating PAH accounted for a significant market share in 2019. Opsumit and Tracleer target ETB and ETA receptors, whereas Volibris/Letairis targets the ETA receptor.

Prostacyclin and its analogs accounted for a significant share in 2019 owing to the significant increase in the sales of this drug for treating pulmonary arterial hypertension. The growing use of oral prostacyclin agents such as Orenitram and Uptravi for the treatment of PAH also contributed to the significant share of the segment.

Regional Insights

North America dominated the PAH market in 2019 owing to the developed healthcare infrastructure in U.S. that facilitates access to advanced therapeutics for treating pulmonary arterial hypertension. Moreover, growing awareness, high diagnosis rate, and supportive government initiatives resulted in an increased demand for PAH treatment. A well-planned reimbursement structure and high awareness resulted in excellent diagnosis rate of PAH. In addition, supportive legislations such as the Rare Disease Act 2002 and the Orphan Drug Act (ODA) 1983 in the U.S. has increased the adoption of novel medication for treating PAH.

Europe followed North America with agencies such as European Medicines Agency (EMA) and the European Society of Cardiology which promote early diagnosis of PAH. The growing prevalence of risk factors and associated diseases such as HIV increases the risk of PAH. Moreover, rising geriatric population, lifestyle changes, and exposure to pollution is anticipated to contribute toward the increasing prevalence of PAH in Europe.

Global pulmonary arterial hypertension market

Asia Pacific is anticipated to register the highest CAGR of 6.7% over the forecast period. Improving healthcare system, rapid economic development, and huge population base drive the need for treating PAH. Moreover, the high disease burden of HIV and diabetes, which are responsible for the development of the PAH, would support the regional market growth over the forecast period.

Pulmonary Arterial Hypertension Market Share Insights

Key players in the PAH market include Johnson & Johnson Services, Inc. (Actelion Pharmaceuticals, Ltd.); Novartis International AG; Gilead Sciences, Inc.; United Therapeutics Corporation; GlaxoSmithKline plc (GSK); Pfizer, Inc.; Dong-A ST Co., Ltd.; Merck Sharp & Dohme Corp; Bayer HealthCare; and Arena Pharmaceuticals.

Key strategies undertaken by these players to increase their foothold in the market for pulmonary arterial hypertension include new product developments, collaborations, and geographical expansions. For instance, as of July 2019, United Therapeutics Corporation launched Remodulin, a medication used to treat adult patients with pulmonary arterial hypertension, wherein the Implantable System for Remodulin is expected to be launched in early 2020. It also plans to file for FDA approval in the first quarter of 2020 for the use of Tyvaso for interstitial lung disease and pulmonary fibrosis. United Therapeutics also plans to widen the market for its PAH drug, Orenitram.

Report Scope



Base year for estimation


Actual estimates/Historical data

2016 - 2018

Forecast period

2020 - 2027

Market representation       

Revenue in USD Million and CAGR from 2020 to 2027

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, U.K., Germany, Italy, Spain, France, China, Japan, India, Australia, South Korea, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE

Report coverage      

Revenue forecast, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global pulmonary arterial hypertension market report on the basis of drug class and region:

  • Drug Class Outlook (Revenue, USD Million, 2016 - 2027)

    • Prostacyclin and Prostacyclin Analogs

    • SGC Stimulators

    • ERA

    • PDE-5

  • Regional Outlook (Revenue, USD Million, 2016 - 2027)

    • North America

      • The U.S.

      • Canada

    • Europe

      • The U.K.

      • Germany

      • Italy

      • Spain

      • France

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

Pricing & Purchase Options

Service Guarantee

  • Insured Buying

    This report has a service guarantee. We stand by our report quality.

  • Confidentiality

    We are in compliance with GDPR & CCPR norms. All interactions are confidential.

  • Custom research service

    Design an exclusive study to serve your research needs.

  • 24/5 Research support

    Get your queries resolved from an industry expert.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities